Press Releases

Press Releases

March 21, 2022
Event to begin at 8:00 AM ET WOBURN, Mass. , March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and
January 10, 2022
CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo ®  on track to release interim data in late 2022 Phase 2 development plan for RP2/3 to
January 4, 2022
WOBURN, Mass. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke , Chief Executive Officer of Replimune ,